Compass Pathways (FRA:5Y6) Interest Expense : €-3.05 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Compass Pathways's interest expense for the three months ended in Mar. 2024 was € -1.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-3.05 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Compass Pathways's Operating Income for the three months ended in Mar. 2024 was € -32.63 Mil. Compass Pathways's Interest Expense for the three months ended in Mar. 2024 was € -1.01 Mil. Compass Pathways did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Compass Pathways Interest Expense Historical Data

The historical data trend for Compass Pathways's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways Interest Expense Chart

Compass Pathways Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.02

Compass Pathways Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-1.01	-1.03	-1.01

Compass Pathways Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.05 Mil.

Compass Pathways (FRA:5Y6) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Compass Pathways's Interest Expense for the three months ended in Mar. 2024 was €-1.01 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-32.63 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €28.00 Mil.

Compass Pathways's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Compass Pathways did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Compass Pathways (FRA:5Y6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (FRA:5Y6) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CMPS:USA

Address

33 Broadwick Street, London, GBR, W1F 0DQ

Website

https://www.compasspathways.com

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways (FRA:5Y6) Headlines

No Headlines